Serum proteins in breast cancer

Area of Science:

• Oncology
• Biochemistry
• Medical Diagnostics

Background:

• Early detection of breast cancer is crucial for effective treatment.
• Plasma protein profiles are increasingly explored as potential biomarkers for various diseases.
• Distinguishing between malignant and benign breast conditions requires reliable diagnostic tools.

Purpose of the Study:

• To determine if plasma protein level changes are characteristic of early breast cancer.
• To compare protein profiles in breast cancer patients versus those with benign breast disease.
• To investigate correlations between plasma protein changes and breast cancer progression.

Main Methods:

• Sequential follow-up of 39 women (18 with breast cancer, 21 with benign disease) for six months.
• Measurement of 10 serum proteins preoperatively and at 3 and 6 months postoperatively.
• Correlation analysis of serum protein levels with clinical scores of tumor spread.

Main Results:

• Breast cancer patients showed significantly higher preoperative beta 2 glycoprotein and six-month postoperative ceruloplasmin levels compared to benign disease patients.
• Significant correlations were observed between serum protein levels and breast cancer progression.
• Specific proteins like ceruloplasmin, prealbumin, hemopexin, alpha 1 antitrypsin, and beta 2 glycoprotein demonstrated correlations with disease status and progression.

Conclusions:

• Specific plasma protein changes, including beta 2 glycoprotein and ceruloplasmin, may serve as indicators for early breast cancer.
• Serum protein levels show correlations with tumor progression, highlighting their potential as prognostic markers.
• Further long-term studies are needed to validate the predictive value of these protein changes for metastasis development.